Clinical research of the value of high-risk CTV setting on intensity-modulated radiotherapy for stage IIB-IVA cervical cancer

被引：0
|
作者：
Yuqi Jiang
Jing Wang
Peng Jiang
Xiang Wang
Lei Zhang
Yongchun Zhang
机构：
[1] The Affiliated Hospital of Qingdao University,Department of Radiation Oncology
来源：
BMC Cancer | / 23卷
关键词：
Uterine cervical neoplasms; Neoplasm recurrence; Intensity modulated radiotherapy; Adverse effects; Simultaneous integrated boost intensity-modulated radiotherapy; High-risk CTV;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer
    Beriwal, Sushil
    Gan, Gregory N.
    Heron, Dwight E.
    Selvaraj, Rai N.
    Kim, Hayeon
    Lalonde, Ron
    Kelley, Joseph L.
    Edwards, Robert P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (01): : 166 - 171
  • [32] Intensity-modulated radiation therapy for advanced cervical cancer: A comparison of dosimetric and clinical outcomes with conventional radiotherapy
    Du, Xue-lian
    TaoJiang
    Sheng, Xiu-gui
    Lu, Chun-hua
    Yu, Hao
    Wang, Cong
    Song, Qu-qing
    Li, Qing-shui
    Pan, Chun-xia
    GYNECOLOGIC ONCOLOGY, 2012, 125 (01) : 151 - 157
  • [33] Clinical significance of intensity-modulated radiotherapy (IMRT) to the distant metastatic lymph nodes for metastatic cervical cancer
    Fang, Chi
    Liu, Suping
    Xia, Jie
    Wu, Xiaohua
    Zhu, Jun
    Ke, Guihao
    BMC CANCER, 2024, 24 (01)
  • [34] A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors
    Shu, Pei
    Shen, Yali
    Zhao, Yaqin
    Xu, Feng
    Qiu, Meng
    Li, Qiu
    Gou, Hongfeng
    Cao, Dan
    Yang, Yu
    Liu, Jiyan
    Yi, Cheng
    Liao, Zhengyin
    Luo, Deyun
    Bi, Feng
    Wang, Xin
    Li, Zhiping
    MEDICAL ONCOLOGY, 2015, 32 (11)
  • [35] A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors
    Pei Shu
    Yali Shen
    Yaqin Zhao
    Feng Xu
    Meng Qiu
    Qiu Li
    Hongfeng Gou
    Dan Cao
    Yu Yang
    Jiyan Liu
    Cheng Yi
    Zhengyin Liao
    Deyun Luo
    Feng Bi
    Xin Wang
    Zhiping Li
    Medical Oncology, 2015, 32
  • [36] Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: Acute toxicity result
    Lim, Tee S.
    Cheung, Patrick C. F.
    Loblaw, D. Andrew
    Morton, Gerard
    Sixel, Katharina E.
    Pang, Geordi
    Basran, Parminder
    Zhang, Liying
    Tirona, Romeo
    Szumacher, Ewa
    Danjoux, Cyril
    Choo, Richard
    Thomas, Gillian
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : 85 - 92
  • [37] Investigation of the added value of high-energy electrons in intensity-modulated radiotherapy:: Four clinical cases
    Korevaar, EW
    Huizenga, H
    Löf, J
    Stroom, JC
    Leer, JWH
    Brahme, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (01): : 236 - 253
  • [38] Efficacy of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate-and high-risk prostate cancer
    Reddy, Krishna
    Strom, Tobin
    Plimpton, Reed
    Kavanagh, Brian D.
    Petersen, Jane
    Wilson, Shandra
    Maroni, Paul
    Raben, David
    JOURNAL OF RADIATION ONCOLOGY, 2014, 3 (04) : 401 - 407
  • [39] Intermediate- and High-Risk Prostate Cancer: A Plea for High-Dose, High-Precision Intensity-Modulated Radiotherapy With a Modulated Duration of Androgen Deprivation Therapy
    Bolla, Michel
    EUROPEAN UROLOGY, 2011, 60 (06) : 1140 - 1141
  • [40] NRG oncology consensus guidelines for delineation of clinical target volumes for intensity-modulated radiotherapy for intact cervical cancer
    Fields, Emma
    Bosch, Walter
    Fisher, Christine
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A102 - A103
12345